[Form 4] Vita Coco Company, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vita Coco Company director Liran Ira reported two securities dispositions on 09/12/2025. The filings show sales of 20,000 and 40,000 shares of common stock executed under a Rule 10b5-1 trading plan, with weighted-average prices reported near $40.00 per share. After the transactions the reporting person is shown as beneficially owning 598,341 shares directly and 742,579 shares indirectly (held by the Ira Liran 2012 Family Trust). The Form 4 was signed by an attorney-in-fact on 09/16/2025.

Positive

• Sales executed under a Rule 10b5-1 trading plan, indicating pre-planned dispositions
• Disclosure includes explanatory footnotes with weighted-average price ranges for transparency
• Form filed and signed by attorney-in-fact, indicating formal submission

Negative

• Dispositions of 60,000 shares (20,000 and 40,000) were reported, which reduce the insider's liquid holdings
• Sales occurred at prices around $40 per share, representing notable insider liquidity on that date
• Some holdings are indirect (742,579 shares held by the Ira Liran 2012 Family Trust), which can complicate direct control assessment

Insights

Securities Analyst

TL;DR: Insider sold 60,000 shares via a Rule 10b5-1 plan; transactions are pre-planned and disclosed.

The Form 4 reports two dispositions totaling 60,000 shares on 09/12/2025 executed pursuant to a Rule 10b5-1 trading plan, with weighted-average prices reported around $40 per share. Such 10b5-1 sales indicate pre-scheduled liquidity rather than ad-hoc insider trading. The filing also discloses continued substantial direct and indirect holdings: 598,341 direct and 742,579 indirect shares (the latter held in the Ira Liran 2012 Family Trust). From an investor disclosure standpoint, the form is consistent with routine insider liquidity and proper SEC reporting.

Corporate Governance Expert

TL;DR: Disclosure appears compliant; sales were covered by a Rule 10b5-1 plan and the Form 4 is executed by attorney-in-fact.

The report explicitly states the sales were effected under a Rule 10b5-1 plan and includes explanatory footnotes describing weighted-average price ranges. The form indicates the reporting person is a company director and the signature was provided by an attorney-in-fact on 09/16/2025. These elements suggest adherence to procedural disclosure requirements. The filing does not include any information about intent or rationale beyond the 10b5-1 designation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Liran Ira

(Last) (First) (Middle)

250 PARK AVE SOUTH

SEVENTH FLOOR

(Street)

NEW YORK NY 10003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vita Coco Company, Inc. [ COCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		S(1)		20,000	D	$40.002(2)	598,341	D
Common Stock	09/12/2025		S(1)		40,000	D	$40.006(3)	742,579	I	by Ira Liran 2012 FT(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.04, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.13, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. These shares are held by the Ira Liran 2012 Family Trust.

	By: Alison Klein, Attorney-in-Fact For: Ira Liran	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Liran Ira report on Form 4 for COCO?

Answer: The Form 4 reports two dispositions on 09/12/2025: 20,000 and 40,000 shares of Vita Coco common stock, sold under a Rule 10b5-1 plan.

At what prices were the COCO shares sold according to the Form 4?

Answer: The filing reports weighted-average prices near $40.00 per share, with footnote ranges from $40.00 to $40.13 depending on the lot.

How many COCO shares does the reporting person beneficially own after the transactions?

Answer: The form shows 598,341 shares owned directly and 742,579 shares owned indirectly (held by the Ira Liran 2012 Family Trust) after the reported transactions.

Were the sales part of a trading plan or ad-hoc trades?

Answer: The sales were effected pursuant to a Rule 10b5-1 trading plan, as stated in the form's explanations.

Who signed the Form 4 and when was it dated?

Answer: The Form 4 was signed by Alison Klein, attorney-in-fact for Ira Liran, and dated 09/16/2025.

What entity holds the indirect shares reported on the Form 4?

Answer: The indirect holdings are held by the Ira Liran 2012 Family Trust, per the explanatory footnote.